Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of REGN13335 in adults with pulmonary arterial hypertension
2024-514754-79-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing REGN13335 with Placebo to REGN13335 (2 arms). Primary endpoint: Change from baseline in pulmonary vascular resistance. Planned start May 2026; status: authorised.
02
Drugs
regn13335
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2024-514754-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514754-79-00.